Citations

Clear

1053 citation(s) found for "Andre, F".

Cardiovascular Regulation During Apnea in Elite Divers
Heusser, Karsten , Džamonja, Gordan , Tank, Jens , Palada, Ivan, Valić, Zoran , Baković, Darija , Obad, Ante , Ivančev, Vladimir, Brešković, Toni , Diedrich, André , Joyner, Michael J. , Luft, Friedrich C. , Dujić, Željko , Jordan, Jens , Joyner, Michael J , Dujić, Željko

Mayo Clinic

Hypertension | March 3, 2009 | Volume: 53 | Issue: 4 | Pages: 719-724

10.1161/hypertensionaha.108.127530 | PMID 19255361 Get It

Involuntary apnea during sleep elicits sustained arterial hypertension through sympathetic activation; however, little is known about voluntary apnea, particularly in elite athletes. Their physiological adjustments are largely unknown. We measured blood pressure, heart rate, hemoglobin oxygen saturation, muscle sympathetic nerve activity, and vascular resistance before and during maximal end-inspiratory breath holds in 20 elite divers and in 15 matched control subjects. At baseline, arterial pressure and heart rate were similar in both groups. Maximal apnea time was longer in divers (1.7±0.4 versus 3.9±1.1 minutes; P <0.0001), and it was accompanied by marked oxygen desaturation (97.6±0.7% versus 77.6±13.9%; P <0.0001). At the end of apnea, divers showed a >5-fold greater muscle sympathetic nerve activity increase ( P <0.01) with a massively increased pressor response compared with control subjects (9±5 versus 32±15 mm Hg; P <0.001). Vascular resistance increased in both groups, but more so in divers (79±46% versus 140±82%; P <0.01). Heart rate did not change in either group. The rise in muscle sympathetic nerve activity correlated with oxygen desaturation ( r 2 =0.26; P <0.01) and with the increase in mean arterial pressure ( r 2 =0.40; P <0.0001). In elite divers, breath holds for several minutes result in an excessive chemoreflex activation of sympathetic vasoconstrictor activity. Extensive sympathetically mediated peripheral vasoconstriction may help to maintain adequate oxygen supply to vital organs under asphyxic conditions that untrained subjects are not able to tolerate voluntarily. Our results are relevant to conditions featuring periodic apnea.
Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials
Sargent, Daniel J. , Sobrero, Alberto , André, Thierry , Green, Erin , Labianca, Roberto , O’Callaghan, Chris J. , Seitz, Jean François, Francini, Guido, Haller, Daniel G. , Yothers, Greg , Goldberg, Richard M. , Gramont, Aimery de , Grothey, Axel , O’Connell, Michael J. , Buyse, Marc , Zheng, Yan , Sargent, Daniel J , André, Thierry , Yothers, Greg

Mayo Clinic

Journal of Clinical Oncology | January 5, 2009 | Volume: 27 | Issue: 6 | Pages: 872-877

10.1200/jco.2008.19.5362 | PMID 19124803 Get It

Purpose Limited data are available on the time course of treatment failures (recurrence and/or death), the nature and duration of adjuvant treatment benefit, and long-term recurrence rates in patients with resected stage II and III colon cancer. Methods The data set assembled by the Adjuvant Colon Cancer Endpoints Group, a collection of individual patient data from 18 trials and more than 20,800 patients testing fluorouracil-based adjuvant therapy in patients with stage II or III colon cancer, was analyzed. Results A significant overall survival (OS) benefit of adjuvant therapy was consistent over the 8-year follow-up period. The risk of recurrence in patients treated with adjuvant chemotherapy never exceeds that of control patients, signifying that adjuvant therapy cures some patients, as opposed to delaying recurrence. After 5 years, recurrence rates were less than 1.5% per year, and after 8 years, they were less than 0.5% per year. Significant disease-free survival (DFS) benefit from adjuvant chemotherapy was observed in the first 2 years. After 2 years, DFS rates in treated and control patients were not significantly different, and after 4 years, no trend toward benefit was demonstrated. This benefit was primarily driven by patients with stage III disease. Conclusion Adjuvant chemotherapy provides significant DFS benefit, primarily by reducing the recurrence rate, within the first 2 years of adjuvant therapy with some benefit in years 3 to 4, translating into long-term OS benefit. This reflects the curative role of chemotherapy in the adjuvant setting. After 5 years, recurrence rates in patients treated on clinical trials are low, and after 8 years, they are minimal; thus, long-term follow-up for recurrence is of little value.
KCNJ11 knockout morula re-engineered by stem cell diploid aggregation
Nelson, Timothy J. , Martinez‐Fernandez, Almudena , Terzic, André , Nelson, Timothy J

Mayo Clinic

Philosophical Transactions of the Royal Society B: Biological Sciences | October 31, 2008 | Volume: 364 | Issue: 1514 | Pages: 269-276

10.1098/rstb.2008.0179 | PMID 18977736 Get It

KCNJ11 -encoded Kir6.2 assembles with ATP-binding cassette sulphonylurea receptors to generate ATP-sensitive K + (K ATP ) channel complexes. Expressed in tissues with dynamic metabolic flux, these evolutionarily conserved yet structurally and functionally unique heteromultimers serve as high-fidelity rheostats that adjust membrane potential-dependent cell functions to match energetic demand. Genetic defects in channel subunits disrupt the cellular homeostatic response to environmental stress, compromising organ tolerance in the adult. As maladaptation characterizes malignant K ATP channelopathies, establishment of platforms to examine progression of K ATP channel-dependent adaptive behaviour is warranted. Chimeras provide a powerful tool to assay the contribution of genetic variance to stress intolerance during prenatal or post-natal development. Here, KCNJ11 K ATP channel gene knockout↔wild-type chimeras were engineered through diploid aggregation. Integration of wild-type embryonic stem cells into zona pellucida-denuded morula derived from knockout embryos achieved varying degrees of incorporation of stress-tolerant tissue within the K ATP channel-deficient background. Despite the stress-vulnerable phenotype of the knockout, ex vivo derived mosaic blastocysts tolerated intrauterine transfer and implantation, followed by full-term embryonic development in pseudopregnant surrogates to produce live chimeric offspring. The development of adult chimerism from the knockout↔wild-type mosaic embryo offers thereby a new paradigm to probe the ecogenetic control of the K ATP channel-dependent stress response.
In Vitro and In Vivo Properties of Adenovirus Vectors with Increased Affinity to CD46
Wang, Hongjie , Liu, Ying , Li, Zong-Yi, Tuve, Sebastian, Stone, Daniel , Kalyushniy, Oleksandr, Shayakhmetov, Dmitry M. , Verlinde, Christophe L. M. J. , Stehle, Thilo , McVey, John H. , Baker, Andrew H. , Peng, Kah-Whye , Roffler, Steve R. , Lieber, André , Baker, Andrew H

Mayo Clinic

Journal of Virology | August 28, 2008 | Volume: 82 | Issue: 21 | Pages: 10567-10579

10.1128/jvi.01308-08 | PMID 18753195 Get It

ABSTRACT Gene transfer vectors containing adenovirus (Ad) serotype 35 (Ad35) fibers have shown promise for cancer and stem cell gene therapy. In this study, we attempted to improve the in vitro and in vivo infection properties of these vectors by increasing their affinity to the Ad35 fiber receptor CD46. We constructed Ad vectors containing either the wild-type Ad35 fiber knob (Ad5/35) or Ad35 knob mutants with 4-fold- and 60-fold-higher affinity to CD46 (Ad5/35+ and Ad5/35++, respectively). In in vitro studies with cell lines, the higher affinities of Ad5/35+ and Ad5/35++ to CD46 did not translate into correspondingly higher transduction efficiencies, regardless of the CD46 receptor density present on cells. However, in vivo, in a mouse model with preestablished CD46 high liver metastases, intravenous injection of Ad5/35++ resulted in more-efficient tumor cell transduction. We conclude that Ad5/35 vectors with increased affinity to CD46 have an advantage in competing with non-CD46-mediated sequestration of vector particles after intravenous injection.
Embryonic Stem Cell Therapy of Heart Failure in Genetic Cardiomyopathy
Nelson, Timothy J. , Crespo‐Diaz, Ruben , Pérez-Terzic, Carmen, Liu, Xiaoke , Seino, Susumu , Behfar, Atta , Yamada, Satsuki , Miki, Takashi , Terzic, André , Behfar, Atta , Nelson, Timothy J , Liu, Xiaoke

Mayo Clinic

Stem Cells | August 1, 2008 | Volume: 26 | Issue: 10 | Pages: 2644-2653

10.1634/stemcells.2008-0187 | PMID 18669912 Get It

Abstract Pathogenic causes underlying nonischemic cardiomyopathies are increasingly being resolved, yet repair therapies for these commonly heritable forms of heart failure are lacking. A case in point is human dilated cardiomyopathy 10 (CMD10; Online Mendelian Inheritance in Man #608569), a progressive organ dysfunction syndrome refractory to conventional therapies and linked to mutations in cardiac ATP-sensitive K+ (KATP) channel subunits. Embryonic stem cell therapy demonstrates benefit in ischemic heart disease, but the reparative capacity of this allogeneic regenerative cell source has not been tested in inherited cardiomyopathy. Here, in a Kir6.2-knockout model lacking functional KATP channels, we recapitulated under the imposed stress of pressure overload the gene-environment substrate of CMD10. Salient features of the human malignant heart failure phenotype were reproduced, including compromised contractility, ventricular dilatation, and poor survival. Embryonic stem cells were delivered through the epicardial route into the left ventricular wall of cardiomyopathic stressed Kir6.2-null mutants. At 1 month of therapy, transplantation of 200,000 cells per heart achieved teratoma-free reversal of systolic dysfunction and electrical synchronization and halted maladaptive remodeling, thereby preventing end-stage organ failure. Tracked using the lacZ reporter transgene, stem cells engrafted into host heart. Beyond formation of cardiac tissue positive for Kir6.2, transplantation induced cell cycle activation and halved fibrotic zones, normalizing sarcomeric and gap junction organization within remuscularized hearts. Improved systemic function induced by stem cell therapy translated into increased stamina, absence of anasarca, and benefit to overall survivorship. Embryonic stem cells thus achieve functional repair in nonischemic genetic cardiomyopathy, expanding indications to the therapy of heritable heart failure. Disclosure of potential conflicts of interest is found at the end of this article.
Can Physicians Accurately Predict Survival Time in Patients with Metastatic Cancer? Analysis of RTOG 97-14
Hartsell, William F. , DeSilvio, Michelle, Bruner, Deborah Watkins , Scarantino, Charles W., Ivker, Robert, Roach, Mack , Demas, William F., Movsas, Benjamin , Petersen, Ivy A. , Konski, André , Suh, John H. , Bruner, Deborah

Mayo Clinic

Journal of Palliative Medicine | June 27, 2008 | Volume: 11 | Issue: 5 | Pages: 723-728

10.1089/jpm.2007.0259 | PMID 18588404 Get It

Progenitor Cell Therapy in a Porcine Acute Myocardial Infarction Model Induces Cardiac Hypertrophy, Mediated by Paracrine Secretion of Cardiotrophic Factors Including TGFβ1
Doyle, Brendan, Sorajja, Paul , Hynes, Brian, Kumar, Arun , Araoz, Phillip A., Stalboerger, Paul G., Miller, Dylan V. , Reed, Cynthia , Schmeckpeper, Jeffrey , Wang, Shaohua , Liu, Chunsheng , Krüger, David , Riederer, Stephen J. , Caplice, Noel M. , Sorajja, Paul , Terzic, André

Mayo Clinic

Stem Cells and Development | June 18, 2008 | Volume: 17 | Issue: 5 | Pages: 941-952

10.1089/scd.2007.0214 | PMID 18564032 Get It

MicroRNA Signatures as Diagnostic and Therapeutic Targets
Waldman, Scott A. , Terzic, André , Waldman, Scott A

Mayo Clinic

Clinical Chemistry | May 28, 2008 | Volume: 54 | Issue: 6 | Pages: 943-944

10.1373/clinchem.2008.105353 | PMID 18509012 Get It

Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set
Campbell, Megan E., Goldberg, Richard M. , Seitz, J. F., Benedetti, Jacqueline, André, Thierry , Haller, Daniel G. , Sargent, Daniel J. , O’Connell, Michael J. , Grothey, Axel , Sargent, Daniel J , André, Thierry

Mayo Clinic

Journal of Clinical Oncology | May 8, 2008 | Volume: 26 | Issue: 14 | Pages: 2336-2341

10.1200/jco.2007.15.8261 | PMID 18467725 Get It

Purpose This study was undertaken to examine five possible prognostic factors in patients with recurrent stage II and III colon cancer: time from randomization on an adjuvant therapy clinical trial to tumor recurrence (< 1 year, 1 to 2 years, 2 to 3 years, 3 to 4 years, > 4 years), initial stage (II v III), initial adjuvant treatment (fluorouracil [FU]-based v surgery alone), the era in which the patient entered an adjuvant therapy clinical trial (1978 to 1985, 1986 to 1992, 1993 to 1999), and patient age at recurrence. Methods The Adjuvant Colon Cancer End Points (ACCENT) data set was analyzed using univariate and multivariate Cox proportional hazards models, stratified by study. Results 5,722 (32.9%) of 17,381 patients experienced recurrence. Median survival following recurrence was 13.3 months. Time from randomization to recurrence was highly prognostic of survival following recurrence (P < .0001). Longer survival following recurrence was seen in patients with initial stage II versus III disease (P < .0001; 14.3% 6-year overall survival after recurrence in initial stage II patients), patients entered more recently onto trials (P < .0001), and patients initially treated with surgery alone versus FU adjuvant treatment (P = .0005). All relationships were maintained in multivariate models. Conclusion Time from initial treatment to recurrence and initial stage are important prognostic factors in patients with recurrent colon cancer. Survival following recurrence increased modestly from 1978 to 1999. Patients who had a recurrence following adjuvant therapy had poorer prognosis than those who progressed after surgery alone. These prognostic factors may be useful for clinical trial design and treatment decisions in patients with recurrent colon cancer.
CXCR4+/FLK-1+ Biomarkers Select a Cardiopoietic Lineage from Embryonic Stem Cells
Nelson, Timothy J. , Faustino, Randolph S. , Chiriac, Anca , Crespo‐Diaz, Ruben , Behfar, Atta , Terzic, André , Behfar, Atta , Nelson, Timothy J

Mayo Clinic

Stem Cells | March 28, 2008 | Volume: 26 | Issue: 6 | Pages: 1464-1473

10.1634/stemcells.2007-0808 | PMID 18369102 Get It

Abstract Pluripotent stem cells demonstrate an inherent propensity for unrestricted multi-lineage differentiation. Translation into regenerative applications requires identification and isolation of tissue-specified progenitor cells. From a comprehensive pool of 11,272 quality-filtered genes, profiling embryonic stem cells at discrete stages of cardiopoiesis revealed 736 transcripts encoding membrane-associated proteins, where 306 were specifically upregulated with cardiogenic differentiation. Bioinformatic dissection of exposed surface biomarkers prioritized the chemokine receptor cluster as the most significantly over-represented gene receptor family during pre cardiac induction, with CXCR4 uniquely associated with mesendoderm formation. CXCR4+ progenitors were sorted from the embryonic stem cell pool into mesoderm-restricted progeny according to co-expression with the early mesoderm marker Flk-1. In contrast to CXCR4−/Flk-1− cells, the CXCR4+/Flk-1+ subpopulation demonstrated overexpressed cardiac lineage transcription factors (Mef2C, Myocardin, Nkx2.5), whereas pluripotent genes (Oct4, Fgf4, Sox2) as well as neuroectoderm (Sox1) and endoderm alpha-fetoprotein markers were all depleted. In fact, the CXCR4+/Flk-1+ biomarker combination identified embryonic stem cell progeny significantly enriched with Mesp-1, GATA-4, and Tbx5, indicative of pre cardiac mesoderm and the primary heart field. Although the CXCR4+/Flk-1+ transcriptome shared 97% identity with the CXCR4−/Flk-1− counterpart, the 818 divergent gene set represented predominantly cardiovascular developmental functions and formed a primitive cardiac network. Differentiation of CXCR4+/Flk-1+ progenitors yielded nuclear translocation of myocardial transcription factors and robust sarcomerogenesis with nascent cardiac tissue demonstrating beating activity and calcium transients. Thus, the CXCR4/Flk-1 biomarker pair predicts the emergence of cardiogenic specification within a pluripotent stem cell pool, enabling targeted selection of cardiopoietic lineage. Disclosure of potential conflicts of interest is found at the end of this article.